Venous Thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE) is one of the most important, potentially preventable, causes of death and morbidity especially of hospitalised patients(1).
Every year it is estimated that:
- One million Europeans suffer from VTE and one third of those will die(1).
- VTE kills more than double the number of people in Europe than breast cancer, prostate cancer, HIV AIDS and traffic accidents combined (1).
- After coronary heart disease and stroke, VTE is the most common cause of cardiovascular death and disability(2).
- In the USA, up to $39.9 BILLION is spent treating preventable hospital acquired VTE every year (3).
- Up to $19.1 BILLION is spent treating the long term effects of hospital acquired VTE (3).
- 50% of all hospital inpatients may be at risk and yet only half receive adequate protection despite the wide availability of effective preventative measures (4).
Flowtron® Intermittent Pneumatic Compression (IPC) therapy can significantly and safely reduce the incidence and severity of VTE.
1 Cohen AT, Agnelli A, Anderson FA et al. Venous thromboembolism (VTE) in Europe: The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756–764.
2 Lowe G. Epidemiology of venous thromboembolism:the need for large(including prospective) studies and meta-analyses.J Thromb Haemost.2012;10:2186-2188
3 Mahan CE, Borrego ME, Woershing AL et al. Venous thromboembolism: Annualised United States model for total, hospital acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012; 108(2): 291-302.
4 Cohen H, Tapson V, Bergmann J et al 2008; Venous thromboembolism risk and prophylaxis in the acute care setting(ENDORSE study): a multi national cross-sectional study.The Lancet:371:387-394